Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the Journal of Clinical Oncology (March 2, 2009).
Maintenance rituximab (Rituxan) following CVP therapy (cyclophosphamide, vincristine, prednisone) improves progression-free survival in patients with stage III/IV indolent lymphoma, according to a phase III study published online ahead of print in the Journal of Clinical Oncology (March 2, 2009).
Researchers looked at 311 patients with stable or responding disease after CVP therapy. At 2 years, an improved disease response was seen in 22% of rituximab-treated patients vs just 7% of control subjects. Toxic effects were minimal in both groups. Three-year progression-free survival was also higher in the maintenance rituximab group: 68% vs 33% in controls.
Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report
Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.
